Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped The study was originally planned to assess four escalating DLs of ruxolitinib (upto 40 mg twice daily), but was closed early due to slow enrollment and changing treatment landscape moving towards less intense approaches.

Conditions

Essential Thrombocythemia
Myelofibrosis
Myeloproliferative Neoplasm
Polycythemia Vera
Secondary Acute Myeloid Leukemia

Interventions

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation
DRUG: Liposome-encapsulated Daunorubicin-Cytarabine
DRUG: Ruxolitinib

Sponsor

Ohio State University Comprehensive Cancer Center

Collaborators

[object Object]
[object Object]